APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+7.36%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$499M
AUM Growth
+$499M
(+2.9%)
Cap. Flow
+$5.91M
Cap. Flow
% of AUM
1.19%
Top 10 Holdings %
Top 10 Hldgs %
49.06%
Holding
80
New
17
Increased
18
Reduced
13
Closed
25
Top Buys
| 1 |
HNGE
Hinge Health, Inc.
HNGE
|
$16.7M |
| 2 |
Intuitive Surgical
ISRG
|
$14.7M |
| 3 |
Natera
NTRA
|
$13.5M |
| 4 |
CG Oncology
CGON
|
$13.5M |
| 5 |
Genmab
GMAB
|
$13.4M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$16.1M |
| 2 |
Glaukos
GKOS
|
$13.2M |
| 3 |
Humana
HUM
|
$13.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$9.93M |
| 5 |
Neurocrine Biosciences
NBIX
|
$9.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
SCYNEXIS
SCYX
$34.8M
| $829K | 0.17% |
1,228,910
| – | – |
|
52
Karyopharm Therapeutics
KPTI
$58.5M
| $580K | 0.12% |
134,566
| – | – |
|
53
Altimmune
ALT
$332M
| $406K | 0.08% |
+105,000
| New | +$406K |
|
54
Enliven Therapeutics
ELVN
$1.23B
| $227K | 0.05% |
11,300
| – | – |
|
55
Reviva Pharmaceuticals
RVPH
$31.8M
| $52.6K | 0.01% |
138,000
| – | – |
|
56
Acadia Pharmaceuticals
ACAD
$4.38B
| – | – |
-169,000
| Closed | -$2.81M |
|
57
Agilon Health
AGL
$522M
| – | – |
-305,100
| Closed | -$1.32M |
|
58
Avantor
AVTR
$9B
| – | – |
-453,000
| Closed | -$7.34M |
|
59
Biohaven
BHVN
$1.75B
| – | – |
-145,000
| Closed | -$3.49M |
|
|
BPMC
60
DELISTED
Blueprint Medicines
BPMC
| – | – |
-68,500
| Closed | -$6.06M |
|
61
Bruker
BRKR
$4.6B
| – | – |
-115,000
| Closed | -$4.8M |
|
62
Capricor Therapeutics
CAPR
$291M
| – | – |
-239,000
| Closed | -$2.27M |
|
|
CNTA
63
Centessa Pharmaceuticals
CNTA
$2.3B
| – | – |
-529,000
| Closed | -$7.61M |
|
|
64
Glaukos
GKOS
$5.38B
| – | – |
-134,000
| Closed | -$13.2M |
|
65
Hyperfine
HYPR
$90.4M
| – | – |
-222,174
| Closed | -$159K |
|
66
IDEAYA Biosciences
IDYA
$2.29B
| – | – |
-445,000
| Closed | -$7.29M |
|
67
Ionis Pharmaceuticals
IONS
$9.66B
| – | – |
-60,000
| Closed | -$1.81M |
|
68
Janux Therapeutics
JANX
$1.37B
| – | – |
-258,000
| Closed | -$6.97M |
|
|
69
Jazz Pharmaceuticals
JAZZ
$7.91B
| – | – |
-80,000
| Closed | -$9.93M |
|
70
Lexeo Therapeutics
LXEO
$260M
| – | – |
-645,000
| Closed | -$2.24M |
|
71
Mirum Pharmaceuticals
MIRM
$3.76B
| – | – |
-40,000
| Closed | -$1.8M |
|
72
NewAmsterdam Pharma
NAMS
$2.8B
| – | – |
-68,000
| Closed | -$1.39M |
|
|
73
Neurocrine Biosciences
NBIX
$14.1B
| – | – |
-85,700
| Closed | -$9.48M |
|
74
Vaxcyte
PCVX
$4.08B
| – | – |
-23,000
| Closed | -$868K |
|
|
75
Regeneron Pharmaceuticals
REGN
$62B
| – | – |
-25,400
| Closed | -$16.1M |
|